A5081565028- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Cardiac electrophysiology and arrhythmias
- Cardiac Imaging and Diagnostics
- Cardiac Arrhythmias and Treatments
- Diabetes Treatment and Management
- Cardiac Valve Diseases and Treatments
- Cardiovascular and exercise physiology
- Hormonal Regulation and Hypertension
- Blood Pressure and Hypertension Studies
- Lipoproteins and Cardiovascular Health
- Atrial Fibrillation Management and Outcomes
- Advanced MRI Techniques and Applications
- Electrolyte and hormonal disorders
- Acute Myocardial Infarction Research
- Congenital Heart Disease Studies
- Cardiovascular Effects of Exercise
- Cardiac Structural Anomalies and Repair
- Potassium and Related Disorders
- Pancreatic function and diabetes
- Cardiac Health and Mental Health
- Heart Rate Variability and Autonomic Control
- Cardiovascular Syncope and Autonomic Disorders
- Erythropoietin and Anemia Treatment
University of Florida Health
2006-2025
Stony Brook University Hospital
2023
University of Florida
2012-2022
Certis USA (United States)
2022
Jacksonville University
1989-2020
Florida College
1989-2020
University of North Florida
2007-2017
Southeast Missouri State University
2016
Duke University
2016
Clinical Research Institute
2016
Previous studies have shown that calcium-channel blockers increase morbidity and mortality in patients with chronic heart failure. We studied the effect of a new blocker, amlodipine, severe failure.We randomly assigned 1153 failure ejection fractions less than 30 percent to double-blind treatment either placebo (582 patients) or amlodipine (571 for 6 33 months, while their usual therapy was continued. The randomization stratified on basis whether had ischemic nonischemic causes primary end...
Background— The mode of death has been well characterized in patients with heart failure and a reduced ejection fraction; however, less is known about the preserved fraction (HFPEF). purpose this study was to examine HFPEF enrolled Irbesartan Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial determine whether irbesartan altered distribution HFPEF. Methods Results— All deaths were reviewed by clinical end-point committee, assigned consensus members. annual mortality rate...
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with and a reduced ejection fraction, without diabetes, but additional data are needed about effect drug on inpatient outpatient events that reflect worsening failure.We randomly assigned 3730 class II to IV an fraction ≤40% double-blind treatment placebo empagliflozin (10 mg once daily), addition recommended treatments failure, median 16 months. We prospectively collected information...
Obesity is a major risk factor for incident heart failure (HF). Paradoxically, in HF with reduced left ventricular ejection fraction (HFREF), high body mass index (BMI) appears to be beneficial. Approximately 50% of patients have preserved (HFPEF). However, there are few data regarding the relationship between BMI and outcomes HFPEF.
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with preserved ejection fraction, but additional data are needed about its effect on inpatient and outpatient events.We randomly assigned 5988 class II through IV an fraction >40% to double-blind treatment placebo empagliflozin (10 mg once daily), addition usual therapy, a median 26 months. We prospectively collected information events reflecting worsening prespecified their analysis...
Background: Advancing age is associated with a greater prevalence of coronary artery disease in heart failure reduced ejection fraction and higher risk complications after bypass grafting (CABG). Whether the efficacy CABG compared medical therapy (MED) patients caused by ischemic cardiomyopathy same different ages unknown. Methods: A total 1212 (median follow-up, 9.8 years) ≤35% amenable to were randomized or MED STICH trial (Surgical Treatment for Ischemic Heart Failure). Results: Mean at...
The assessment of arterial stiffness is increasingly used for evaluating patients with different cardiovascular diseases as the mechanical properties major arteries are often altered. Aortic can be noninvasively estimated by measuring pulse wave velocity (PWV). Several methods have been proposed PWV using velocity-encoded magnetic resonance (CMR), including transit-time (TT), flow-area (QA), and cross-correlation (XC) methods. However, comparison these techniques at high field strength has...
Pharmacogenetics involves complex interactions of gene products affecting pharmacodynamics and pharmacokinetics, but there is little information on the interaction multiple genetic modifiers drug response. Bucindolol a β-blocker/sympatholytic agent whose efficacy modulated by polymorphisms in primary target (β(1) adrenergic receptor [AR] Arg389 Gly cardiac myocytes) secondary modifier (α(2C) AR Ins [wild-type (Wt)] 322-325 deletion [Del] neurons). The major allele homozygotes minor carriers...
In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis significantly reduced mortality and cardiovascular (CV)-related hospitalizations compared with placebo patients transthyretin amyloid cardiomyopathy (ATTR-CM). This analysis aimed to assess causes of CV-related death hospitalization ATTR-ACT provide further insight into progression ATTR-CM efficacy tafamidis. was an international, double-blind, placebo-controlled, randomized study. Patients hereditary or...